Login with Linked

Follow us on

Link Linkedin Youtube

Yorvipath

Yorvipath is used to treat hypoparathyroidism. It is a ready-to-use injection that is administered once a day to people with hypoparathyroidism.

Molecule Details :

  • Molecule Name :

    Palopegteriparatide

  • Innovator :

    ASCENDIS PHARMA BONE DISEASES AS

  • Approval Date :

    09-Aug-24

  • NCE-1 Date :

    09-Aug-28

  • NCE Date :

    09-Aug-29

  • Dosage Form :

    Subcutaneous Solutions

  • Strength :

    EQ 0.168MG , EQ 0.294MG & EQ 0.42MG

  • Therapeutic Category :

    Hormonal Therapy

  • Revenue ($M) :

    31

Year-wise Projected Sales ($M) :

  • 2025 :

    372

  • 2026 :

    745

  • 2027 :

    1,159

  • 2028 :

    1,554

  • 2029 :

    1,872

  • 2030 :

    2,118

  • 2031 :

    2,413
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?